Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neoprobe to submit phase II/III Lymphoseek trial data to FDA:

This article was originally published in Clinica

Executive Summary

After meeting the primary endpoint in a phase II clinical trial of its Lymphoseek tracer, Neoprobe is preparing to submit both phase II and phase III clinical trials data to the US FDA. The primary endpoint in the phase II trial was for Lymphoseek (Technetium Tc99m DTPA-mannosyl-dextran) to achieve 90% localisation to lymphoid tissue - localisation was reported in 94% of the procedures performed during the study, which was carried out in breast cancer and melanoma patients. Neoprobe, based in Dublin, Ohio, now plans to begin "winding down" its phase II trial activities, collecting 30-day patient safety follow-up information and accumulating data to report to the agency. Lymphoseek is a radioactive targeting agent developed for use with handheld gamma detection devices, such as Neoprobe's neo2000 system, during the surgical procedure, sentinel lymph node biopsy (SLNB).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049063

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel